Molecule Details
InChIKeyWDHOIABIERMLGY-CMJOXMDJSA-N
Compound NameCamizestrant
Canonical SMILESC[C@@H]1Cc2c(ccc3[nH]ncc23)[C@@H](c2ccc(NC3CN(CCCF)C3)cn2)N1CC(F)(F)F
Clinical Status Data-mined Candidate
Targets (Human+Pathogen)3
Pfam Stratification Cross-Family
Avg pChEMBL8.0
SourceChEMBL;BindingDB
2D Structure
2D structure
Activity Profile
DrugBank Annotations
DrugBank ID DB19218
Drug NameCamizestrant
CAS Number2222844-89-3
Groups investigational
ATC Codes nan
DescriptionCamizestrant is under investigation in clinical trial NCT05952557 (An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)).
Categories: Azetines Heterocyclic Compounds, Fused-Ring
Cross-references: CHEMBL4650365 ChemSpider: 103820855
Target Activities (3)
Target Gene Organism Category Pfam pChEMBL Type Source
P03372 ESR1 Homo sapiens Human PF12743 PF00104 PF02159 PF00105 8.8 IC50 ChEMBL;BindingDB
Q12809 KCNH2 Homo sapiens Human PF00027 PF00520 PF13426 8.7 IC50 ChEMBL;BindingDB
Q9Y5N1 HRH3 Homo sapiens Human PF00001 6.5 IC50 ChEMBL;BindingDB
DrugBank Target Actions (1)
Target Gene Target Name Action Type
P03372 ESR1 Estrogen receptor degradation targets